3i’s North American arm will begin an aggressive expansion of its healthcare team, Robin Marshall, a senior partner at New York-based 3i North America Growth Capital has told PrivateEquityOnline.
He said London-headquartered 3i is eager to establish a greater presence in North America’s sprawling healthcare industry following successful investments such as Quintiles Transnational, a North Carolina drug-development services business, and other deals in the sector.
Over the past year, listed 3i has committed more than $1.5 billion (€962 million) to healthcare deals. “We intend to maintain this momentum by strengthening our US team over the next year,” said Marshall. “The US and Canada are home to some of the best healthcare businesses in the world. . . With 3i’s unparalleled international network, we are uniquely positioned to be an outstanding partner for growing businesses in this sector.”
Other recent 3i healthcare deals have included Labco, a pan-European medical diagnostics company, Ultralase, a UK laser eye-surgery clinic and Alpharma API, a pharmaceutical-ingredients company.